Several research firms recently issued [â¦] 0.6 Earnings and Valuation Earnings Growth Earnings for Real time Dyne Therapeutics, Inc. (DYN) stock price quote, stock graph, news & analysis. Find the latest VYNE Therapeutics Inc. (VYNE) stock quote, history, news and other vital information to help you with your stock trading and investing. VYNE VYNE Therapeutics Inc Latest News. The companyâs stock price has collected 11.94% of gains in the last five trading Vyne Therapeutics (VYNE) stock is taking off on Wednesday as investors take an interest in the pharmaceutical company on recent news. Menlo Therapeutics says midstage trial of treatment for chronic pruritus failed to meet goals. VYNE Therapeutics (VYNE Therapeutics: VYNE) stock research, analysis, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers. View VYNE's stock price, price target, earnings, forecast, insider trades, and news at MarketBeat. Northland Securities Reaffirms Their Buy Rating on VYNE Therapeutics (VYNE) VYNE Therapeutics Inc. VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. * VYNE THERAPEUTICS ( VYNE ) - PRELIMINARY ESTIMATE OF CASH, CASH EQUIVALENTS, RESTRICTED CASH AND INVESTMENTS IS ABOUT $59.0 MILLION ⦠As is evident from the statistics, the companyâs shares have risen +11.97 percent over the past six months and at a -53.87% annual growth rate that is well below the industry average of 16.9%. The companyâs stock... VYNE Therapeutics Inc. (NASDAQ:VYNE) changed by 0.00% from its VYNE Therapeutics Inc. (NASDAQ:VYNE) shot up 5.3% during mid-day trading on Wednesday . VYNE Therapeutics stock quote and VYNE charts. 1)* VYNE Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of ⦠Breaking news and media archive for VYNE Therapeutics Inc. ( VYNE ) and the biotechnology sector including press releases, Stockhouse reporting, and the Canadian Press Stockhouse.com use cookies on this site. VYNE Therapeutics Inc. (NASDAQ:VYNE) went up by 5.28% from its latest closing price compared to the recent 1-year high of $14.40. The Quote Overview page gives you a snapshot view for a specific symbol. Vyne Therapeutics Inc (VYNE): * Vyne Therapeutics Inc (VYNE) - PRELIMINARY ESTIMATE OF TOTAL REVENUES FOR QUARTER ENDED DECEMBER 31, 2020 IS IN RANGE OF $4.0 MILLION TO $4.5 MILLION. Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer March 04, 2021 Seasoned Clinical Leader Brings Deep Experience in Drug Development, Including Approval of an Oligonucleotide Therapy Vyne Therapeutics (VYNE) stock is taking off on Wednesday as investors take an interest in the pharmaceutical company on recent news. Get Vyne Therapeutics Inc (VYNE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Latest news headlines for Vyne Therapeutics Inc with market analysis and analyst commentary. The AP news staff was not involved in its creation. Skip to main content Market Activity CLOSE Market Activity Stocks Funds + ⦠Get news for Nasdaq companies quoted on the stock market, press releases, financial disclosures and multimedia content, for investment community, individual investors and View the latest VYNE Therapeutics Inc. (VYNE) stock price, news, historical charts, analyst ratings and financial information from WSJ. Free real-time prices, trades, and chat. VYNE Therapeutics Inc. (NASDAQ:VYNE) went up by 2.82% from its latest closing price compared to the recent 1-year high of $7.48. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Based on an average trading volume of 2,200,000 shares, the days-to-cover ratio is presently 1.2 days. VYNE Therapeutics Inc. NASDAQ Updated Mar 17, 2021 10:41 PM P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a ⦠A high-level overview of VYNE Therapeutics Inc. (VYNE) stock. Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use. Researching VYNE Therapeutics (NASDAQ:VYNE) stock? Vyne Therapeutics Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. The stock had previously closed at $7.39. 1,362,176 shares traded hands during trading, a decline of 50% from the average session volume of 2,733,003 shares. Latest stock price today and the US's most active stock market forums. What You Need To Know About The VYNE Therapeutics Inc. (NASDAQ:VYNE The company report on February 11, 2021 that VYNE Therapeutics Announces Reverse Stock Split. VYNE Therapeutics Inc. [NASDAQ: VYNE] loss -10.57% or -1.07 points to close at $9.05 with a heavy trading volume of 4323649 shares. Latest Stock Picks Investing Basics Premium Services ⦠VYNE / VYNE Therapeutics Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment 02-16 sec.gov - 3 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. The AP news staff was not involved in its creation. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. Find the latest news headlines from VYNE Therapeutics Inc. Common Stock (VYNE) at Nasdaq.com. Hereâs everything investors need to know about VYNE ⦠Real time VYNE Therapeutics Inc. (VYNE) stock price quote, stock graph, news & analysis. Register now to watch these stocks streaming on the ADVFN Monitor. The stock traded as high as $7.87 and last traded at $7.78. Press release content from Globe Newswire. VYNE Therapeutics News: This is the News-site for the company VYNE Therapeutics on Markets Insider As of February 26th, there was short interest totalling 2,720,000 shares, a drop of 71.8% from the February 11th total of 9,660,000 shares. VYNE Therapeutics Inc., which has a market valuation of $502.6 Million, is expected to release its quarterly earnings report in Apr 2021. VYNE Therapeutics Inc. (NASDAQ:VYNE) was the target of a significant drop in short interest in the month of February. Find recent news headlines for a specific symbol on this page. Menlo Therapeutics shares halted premarket for news pending. VYNE Therapeutics shares are trading higher after HC Wainwright & Co maintained its Buy rating on the stock and raised its price target from $3 ⦠VYNE Therapeutics Inc. (VYNE) projections and forecasts VYNE Therapeutics Inc. share prices are not performing particularly well compared to other companies within the same industry. Press release content from Globe Newswire. VYNE Therapeutics news and VYNE price.